Greenhaven Road Capital cites LFCR’s seven new customer wins but notes revenue delays due to FDA approval timelines.
Lifecore Biomedical (NASDAQ:LFCR) closed at $4.72 on August 14, 2026, valuing the company at $178.67 million. Shares have fallen 38.78% over the past 52 weeks and declined 3.41% in the last month.
The contract development and manufacturing firm added seven new customers in nine months, signaling progress under its revamped sales team. However, lengthy FDA approval processes delay revenue recognition, limiting near-term investor enthusiasm.
Greenhaven Road Capital remains optimistic, citing sticky contracts and potential for higher valuations as approvals materialize.